$16.39
1.459.71%
At Close: -
$16.34
-0.05-0.31%
After Hours: 7:59 PM EDT
15 minutes delayed
Comments
Loading...
Novavax
NVAXNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Novavax (NASDAQ:NVAX) Stock, Analyst Ratings, Price Targets, Forecasts
Novavax Inc has a consensus price target of $54.43 based on the ratings of 7 analysts. The high is $168 issued by Cantor Fitzgerald on June 8, 2022. The low is $10 issued by TD Cowen on May 13, 2024. The 3 most-recent analyst ratings were released by B of A Securities, B. Riley Securities, and HC Wainwright & Co. on June 14, 2024, May 23, 2024, and May 13, 2024, respectively. With an average price target of $22 between B of A Securities, B. Riley Securities, and HC Wainwright & Co., there's an implied 34.65% upside for Novavax Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
B of A Securities
B. Riley Securities
HC Wainwright & Co.
TD Cowen
JP Morgan
1calculated from analyst ratings
Analyst Ratings for Novavax
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/14/2024 | Buy Now | 10.17% | B of A Securities | Alec Stranahan | $12 → $18 | Maintains | Neutral | Get Alert |
| 05/23/2024 | Buy Now | 77.49% | B. Riley Securities | Mayank Mamtani | $11 → $29 | Maintains | Buy | Get Alert |
| 05/13/2024 | Buy Now | 16.29% | HC Wainwright & Co. | Vernon Bernardino | → $19 | Reiterates | Buy → Buy | Get Alert |
| 05/13/2024 | Buy Now | -38.79% | TD Cowen | Brendan Smith | $5 → $10 | Maintains | Hold | Get Alert |
| 05/10/2024 | Buy Now | -26.55% | B of A Securities | Alec Stranahan | $4 → $12 | Upgrade | Underperform → Neutral | Get Alert |
| 03/01/2024 | Buy Now | 16.29% | HC Wainwright & Co. | Vernon Bernardino | $35 → $19 | Maintains | Buy | Get Alert |
| 02/23/2024 | Buy Now | -32.67% | B. Riley Securities | Mayank Mamtani | $12 → $11 | Maintains | Buy | Get Alert |
| 11/10/2023 | Buy Now | -26.55% | B. Riley Securities | Mayank Mamtani | $15 → $12 | Maintains | Buy | Get Alert |
| 08/10/2023 | Buy Now | 114.22% | HC Wainwright & Co. | Vernon Bernardino | → $35 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | -8.19% | B. Riley Securities | Mayank Mamtani | → $15 | Upgrade | Neutral → Buy | Get Alert |
| 05/10/2023 | Buy Now | 114.22% | HC Wainwright & Co. | Vernon Bernardino | $110 → $35 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | -38.79% | B. Riley Securities | Mayank Mamtani | $29 → $10 | Downgrade | Buy → Neutral | Get Alert |
| 02/13/2023 | Buy Now | 573.26% | HC Wainwright & Co. | Vernon Bernardino | → $110 | Reiterates | → Buy | Get Alert |
| 01/02/2023 | Buy Now | 573.26% | HC Wainwright & Co. | Vernon Bernardino | $207 → $110 | Maintains | Buy | Get Alert |
| 10/14/2022 | Buy Now | 408% | B. Riley Securities | Mayank Mamtani | $126 → $83 | Maintains | Buy | Get Alert |
| 09/22/2022 | Buy Now | 65.25% | JP Morgan | Eric Joseph | $132 → $27 | Downgrade | Neutral → Underweight | Get Alert |
| 08/09/2022 | Buy Now | 573.26% | Cowen & Co. | Georgi Yordanov | $150 → $110 | Maintains | Outperform | Get Alert |
| 06/08/2022 | Buy Now | 928.25% | Cantor Fitzgerald | Charles Duncan | $146 → $168 | Maintains | Overweight | Get Alert |
| 05/20/2022 | Buy Now | — | B of A Securities | Alec Stranahan | — | Initiates | → Underperform | Get Alert |
| 04/26/2022 | Buy Now | 1142.46% | B. Riley Securities | Mayank Mamtani | $250 → $203 | Maintains | Buy | Get Alert |
| 03/03/2022 | Buy Now | 1166.95% | HC Wainwright & Co. | Vernon Bernardino | $294 → $207 | Maintains | Buy | Get Alert |
| 01/21/2022 | Buy Now | 818.08% | Cowen & Co. | Georgi Yordanov | → $150 | Initiates | → Outperform | Get Alert |
| 12/21/2021 | Buy Now | 1179.19% | JP Morgan | Eric Joseph | $172 → $209 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for Novavax (NVAX) stock?
The latest price target for Novavax (NASDAQ:NVAX) was reported by B of A Securities on June 14, 2024. The analyst firm set a price target for $18.00 expecting NVAX to rise to within 12 months (a possible 10.17% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Novavax (NVAX)?
The latest analyst rating for Novavax (NASDAQ:NVAX) was provided by B of A Securities, and Novavax maintained their neutral rating.
When was the last upgrade for Novavax (NVAX)?
The last upgrade for Novavax Inc happened on May 10, 2024 when B of A Securities raised their price target to $12. B of A Securities previously had an underperform for Novavax Inc.
When was the last downgrade for Novavax (NVAX)?
The last downgrade for Novavax Inc happened on March 1, 2023 when B. Riley Securities changed their price target from $29 to $10 for Novavax Inc.
When is the next analyst rating going to be posted or updated for Novavax (NVAX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Novavax, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Novavax was filed on June 14, 2024 so you should expect the next rating to be made available sometime around June 14, 2025.
Is the Analyst Rating Novavax (NVAX) correct?
While ratings are subjective and will change, the latest Novavax (NVAX) rating was a maintained with a price target of $12.00 to $18.00. The current price Novavax (NVAX) is trading at is $16.34, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.